Full TitlePhase II Pilot Study of a Geriatric Assessment-Driven, Risk-Adapted Allogeneic Hematopoietic Cell Transplant Strategy for Older Patients with Myeloid Malignancies
Giving stem cells from a donor (allogeneic stem cell transplant) is a common treatment for blood cancers and disorders. The standard approach for older patients (age 60+) who are going to receive this treatment is for doctors to plan treatment based on that person’s diagnosis (what disease the patient has), how the disease is affecting the patient (disease status), and the patient’s overall health.
In this study, researchers will determine whether adding a geriatric assessment to this process can help determine the best treatment approach for older patients who are going to receive chemotherapy or another treatment to prepare for an allogeneic stem cell transplant for myelodysplastic syndromes (MDS), myeloproliferative neoplasms, or related blood disorders. The geriatric assessment looks at patients’ cognitive function (thinking processes), physical function, mobility (ability to move), mood, nutrition, and current medications. The researchers will see if using a geriatric assessment leads to better treatment outcomes and quality of life for these patients.
Patients in this study include those age 60 and older who will be receiving an allogeneic stem cell transplant for MDS, myeloproliferative neoplasms, or related blood disorders, including chronic myelomonocytic leukemia, atypical chronic myeloid leukemia, and myelodysplastic/myeloproliferative overlapping syndrome.
For more information about this study and to inquire about eligibility, please contact Dr. Richard J. Lin at 646-830-1008.